Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2016 Mar;14(3):255-64.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Author information

1
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2
University of Washington/Seattle Cancer Care Alliance
3
Huntsman Cancer Institute at the University of Utah
4
UC San Diego Moores Cancer Center
5
Fox Chase Cancer Center
6
University of Colorado Cancer Center
7
Roswell Park Cancer Institute
8
Dana-Farber/Brigham and Women’s Cancer Center
9
Duke Cancer Institute
10
Moffitt Cancer Center
11
University of Alabama at Birmingham Comprehensive Cancer Center
12
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
13
Vanderbilt-Ingram Cancer Center
14
UCSF Helen Diller Family Comprehensive Cancer Center
15
The University of Texas MD Anderson Cancer Center
16
Fred & Pamela Buffett Cancer Center
17
Massachusetts General Hospital Cancer Center
18
Yale Cancer Center/Smilow Cancer Hospital
19
University of Michigan Comprehensive Cancer Center
20
The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute
21
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
22
City of Hope Comprehensive Cancer Center
23
Memorial Sloan Kettering Cancer Center
24
Mayo Clinic Cancer Center
25
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
26
St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center
27
National Comprehensive Cancer Network

Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

PMID:
26957612
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center